Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 216

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 216
---
 Midatech Pharma (Wales) Limited were subsequently changed to Biodexa Ltd and Biodexa Pharmaceuticals
(Wales) Limited, respectively.

Our principal executive office
and registered offices are located at 1 Caspian Point, Caspian Way Cardiff, United Kingdom CF10 4DQ, and our telephone number is +44 29
2048 0180. Our authorized representative in the United States is Donald J. Puglisi of Puglisi and Associates. Our agent for service in
the United States is Donald J. Puglisi of Puglisi and Associates, located at 850 Library Avenue, Suite 204, Newark, Delaware 19711. Our
Depositary Shares are traded on the NASDAQ Capital Market under the symbol “BDRX.”

We file reports and other
information with the SEC. The SEC maintains an Internet website that contains reports, proxy and information statements, and other information
regarding issuers, including us, that file electronically with the SEC. Our filings with the SEC are available to the public through the
SEC’s website athttp://www.sec.gov. Our corporate website is located at www.biodexapharma.com. Information contained
on our website is not part of, or incorporated in, this prospectus.

We have three wholly owned
subsidiaries, as well as several indirectly owned subsidiaries and joint ventures. The following table sets forth a description of the
Group.

| Subsidiaries                                | Country of Incorporation | Voting Interest |
| Subsidiaries of Biodexa Pharmaceuticals PLC |                          |                 |
| Biodexa Pharmaceuticals (Wales) Limited     | England and Wales        | 100%            |
| Biodexa Ltd                                 | England and Wales        | 100%            |
| Haaland UK Limited (1)                      | England and Wales        | 100%            |
| Subsidiaries of Biodexa Ltd                 |                          |                 |
| Pharmida AG (1)                             | Switzerland              | 100%            |

_______________

| (1) | Dormant entities. |

| 107 |

Capital Expenditures

Our capital expenditures amounted
to £Nil and £4,000 for the six months ended for the six months ended June 30, 2024 and 2023, and £0.03 million and £0.06
million for the years ended December 31, 2023 and 202